VELUM INC
Cambridge, MA · Biotech · Private
Peptide therapeutics with protease-resistant modifications to extend half-life and efficacy
- Grants
- $6.5M
- 15 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification | $222,678 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification | $222,678 | |
| Federal grant | Department of Health and Human Services · Phase I · A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid High-Fidelity Assembly of Challenging Peptide Sequences | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid High-Fidelity Assembly of Challenging Peptide Sequences | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Triagonist Peptide Therapeutics for Neuroprotection | $259,613 | |
| Federal grant | Department of Health and Human Services · Phase II · A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $488,486 | |
| Federal grant | Department of Health and Human Services · Phase I · Triagonist Peptide Therapeutics for Neuroprotection | $259,613 | |
| Federal grant | Department of Health and Human Services · Phase I · Protease Stable N-Terminally Modified Therapeutic Peptides | $367,389 | |
| Federal grant | Department of Health and Human Services · Phase I · Protease Stable N-Terminally Modified Therapeutic Peptides | $367,389 | |
| Federal grant | Department of Health and Human Services · Phase II · A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $738,741 | |
| Federal grant | Department of Health and Human Services · Phase II · A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $478,280 | |
| Federal grant | Department of Health and Human Services · Phase II · A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome | $1,135,509 | |
| Federal grant | Department of Health and Human Services · Phase I · Peptide YY triagonist weight loss drugs | $315,342 | |
| Federal grant | Department of Health and Human Services · Phase II · A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome | $959,031 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3220 | TARGAZYME, INC. | — | — |
| 3221 | Rondo Therapeutics | — | — |
| 3222 | GROW BIOMEDICINE LLC | — | — |
| 3223 | VELUM INC | — | — |
| 3224 | Proneurogen, Inc | — | — |
| 3225 | CLARADELE PHARMACEUTICALS, INCORPORATED | — | — |
| 3226 | Quercus Molecular Design, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.